Format

Send to

Choose Destination
Clin Gastroenterol Hepatol. 2019 Jul 10. pii: S1542-3565(19)30739-6. doi: 10.1016/j.cgh.2019.07.006. [Epub ahead of print]

Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients.

Author information

1
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: jallegretti@bwh.harvard.edu.
2
Finch Therapeutics Group, Somerville, Massachusetts.
3
Division of Integrative Systems Medicine and Digestive Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
4
Division of Gastroenterology, Jefferson University, Philadelphia, Pennsylvania.
5
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
6
Openbiome, Cambridge, Massachusetts.
7
Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Abstract

BACKGROUND & AIMS:

Studies in mice have shown that the intestinal microbiota can contribute to obesity via the anorexigenic gut hormone glucagon-like peptide 1 (GLP1) and bile acids, which affect lipid metabolism. We performed a randomized, placebo-controlled, pilot study of the effects of fecal microbiota transplantation (FMT) in obese, metabolically uncompromised patients.

METHODS:

We performed a double-blind study of 22 obese patients (body mass index [BMI] ≥5 kg/m2) without a diagnosis of diabetes, nonalcoholic steatohepatitis, or metabolic syndrome. Participants were assigned randomly (1:1) to groups that received FMT by capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8) or placebo capsules. FMT capsules were derived from a single lean donor (BMI, 17.5 kg/m2). Patients were followed up through week 26; the primary outcome was safety. Stool and serum samples were collected from patients at baseline and at weeks 1, 4, 6, 8, and 12 after administration of the first dose of FMT or placebo and analyzed by 16S RNA gene sequencing. Stool and serum samples were analyzed for metabolomics by liquid chromatography-mass spectrometry. Additional outcomes were the change in area under the curve for GLP1 at week 12.

RESULTS:

We observed no significant differences in adverse events between patients who received FMT vs placebo. There was no increase in the area under the curve of GLP1 in either group. Patients who received FMT had sustained shifts in microbiomes associated with obesity toward those of the donor (P < .001). Patients who received FMT had a sustained decrease in stool levels of taurocholic acid (P < .05) compared with baseline; bile acid profiles began to resemble those of the donor more closely. We did not observe significant changes in mean BMI at week 12 in either group.

CONCLUSIONS:

In a placebo-controlled pilot study, we found that FMT capsules (derived from a lean donor) were safe but did not reduce BMI in obese metabolically uncompromised patients. The FMT capsules were well tolerated and led to sustained changes in the intestinal microbiome and bile acid profiles that were similar to those of the lean donor. ClinicalTrials.gov number: NCT02741518.

KEYWORDS:

Bacteria; Bile Acids; Microbe; Overweight; Treatment

PMID:
31301451
DOI:
10.1016/j.cgh.2019.07.006

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center